MediciNova (NASDAQ:MNOV) & Phibro Animal Health (NASDAQ:PAHC) Head to Head Comparison

MediciNova (NASDAQ:MNOV) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.

Volatility & Risk

MediciNova has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.

Insider and Institutional Ownership

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 48.5% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares MediciNova and Phibro Animal Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Phibro Animal Health	6.57%	37.86%	9.18%

Analyst Recommendations

This is a summary of recent recommendations and price targets for MediciNova and Phibro Animal Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1	1	4	1	2.71
Phibro Animal Health	0	2	1	1	2.75

MediciNova currently has a consensus price target of $7.75, suggesting a potential upside of 416.67%. Phibro Animal Health has a consensus price target of $47.67, suggesting a potential upside of 29.49%. Given MediciNova’s higher probable upside, equities research analysts plainly believe MediciNova is more favorable than Phibro Animal Health.

Earnings and Valuation

This table compares MediciNova and Phibro Animal Health”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410,000.00	180.07	-$12.00 million	($0.21)	-7.14
Phibro Animal Health	$1.52 billion	0.98	$99.72 million	$2.44	15.09

Phibro Animal Health has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Summary

Phibro Animal Health beats MediciNova on 9 of the 13 factors compared between the two stocks.

About MediciNova

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.